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Available online 24 December 2015Background: Sertoli–Leydig cell tumors are rare sex-cord stromal tumors of the ovary that can present with a
variety of histological elements, which may complicate diagnosis and treatment.
Case: A 40-year-old female presenting with pelvic pain is found to have a large complex right adnexal mass and
elevated alpha-fetoprotein. The mass was diagnosed as a Sertoli–Leydig cell tumor with heterologous elements
including carcinoid and hepatoid components. She was treated with surgical resection followed by adjuvant
chemotherapy and remains clear of disease.
Conclusion: Prognostic indicators for Sertoli–Leydig cell tumors include degree and type of heterologous element
differentiation. Thorough characterization of such elements is crucial for adequate diagnosis and treatment.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Sertoli–Leydig
Sex-cord
Carcinoid
Hepatoid
Alphafetoprotein
Endometrioid1. Introduction
Sertoli–Leydig cell tumors (SLCTs) are rare tumors, accounting for
less than 0.5% of all ovarian cancers (DiSaia and Creasman, 1997). The
varying histopathology and differentiation of this tumor present difﬁ-
culties with proper diagnosis and development of optimal treatment
regimens. The prevalence of Sertoli–Leydig tumorswith hepatoid differ-
entiation is exceedingly uncommon with few published case reports,
resulting in an additional diagnostic dilemma. We report the case of a
Sertoli–Leydig cell tumor found in a 40-year-old femalewith intermedi-
ate differentiation and heterologous elements including endometrioid
and hepatoid differentiation with alpha-fetoprotein expression.
2. Case
The patient is a 40-year-old female with a past medical history of
morbid obesity (bodymass index 54.3 kg/m2), abnormal uterine bleed-
ing status post-endometrial ablation, and extensive abdominal surger-
ies, including three cesarean sections and repair of a large ventral
hernia with mesh, who presented to the emergency department with
a chief complaint of progressive left lower quadrant abdominal pain
over a period of ﬁve years. On abdominal computed tomography (CT)
and ultrasound imaging, she was found to have a 13 cm complex right
adnexal mass. Diagnostic studies showed an isolated elevation of ther MD Anderson Cancer Center,
USA.
.com (M.P. Schlumbrecht).
. This is an open access article underserum alpha-fetoprotein tumor marker. She was taken to the operating
room where initial exploration noted no evidence of disseminated dis-
ease but, due to extensive adhesions fromher prior surgeries, prolonged
adhesiolysis was performed, including resection of a portion of small
bowel densely adherent to the previously placed abdominal wall
mesh. Once visualized, the right adnexal mass was excised, with frozen
section noting ovarian neoplasm, favor malignant, with suspicion for
mucinous components. The left ovary was also grossly abnormal in ap-
pearance, so it too was removed. Given the suspected mucinous tumor,
additional procedures performed included omentectomy and appen-
dectomy. Lymphadenectomy was not performed given the mucinous
histology. Final pathology, however, noted a moderately differentiated
Sertoli–Leydig cell tumor with heterologous elements, including liver
tissue demonstrating alpha-fetoprotein expression, conﬁned to the
right ovary [Fig. 1]. Benign pathology was noted on the left ovary.
Shortly following surgery, the patient's serum alpha-fetoprotein
level returned to normal. She received 2 cycles of carboplatin and
paclitaxel, which was poorly tolerated and met with signiﬁcant side
effects. She was admitted following cycle 1 for intractable nausea
and was noted to have chronic Helicobacter pylori infection on
esophagogastroduodenoscopy. Following cycle 2, she was treated for
possible shingles and continued to have signiﬁcant abdominal pain
and nausea. Subsequent to multiple emergency room visits, she had a
CT scan showing no evidence of recurrent or residual disease as well
as no additional acute ﬁndings. In light of her poor tolerance to themed-
ications and favorable ﬁndings at time of surgery, the decision was
made in conjunction with the patient to discontinue chemotherapy.
To date, she has remained without evidence of disease for 20 months.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Immunohistochemical staining of Sertoli–Leydig cell tumor. (A): Sertoli–Leydig cell tumor, intermediate grade with hepatoid differentiation. (B): Area of carcinoid tumor.
(C): Immunohistochemical stain alpha-fetoprotein (AFP) positive in the area of hepatoid differentiation. (D): Immunohistochemical stain chromogranin positive in the carcinoid tumor.
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Ovarian sex cord-stromal tumors are a heterogeneous group of ovar-
ian tumors that comprise only 1.2% of all primary ovarian cancers
(DiSaia and Creasman, 1997). Sertoli–Leydig cell tumors (SLCTs), also
called androblastomas, are a subset of ovarian sex cord-stromal tumors
that constitute less than 0.5% of all ovarian tumors (DiSaia and
Creasman, 1997). SLCTs are characterized as well differentiated, inter-
mediately differentiated, and poorly differentiated, with the degree of
differentiation corresponding to patient prognosis (Chen et al., 2014;
Young and Scully, 1985). These tumors most often occur in young
women 20 to 30 years old, are unilateral, conﬁned to the ovary, and
large (Young and Scully, 1985). Though frequently characterized by
the presence of androgen production, only 30% of patients display
virilization or defeminization on presentation (Young and Scully,
1985). Speciﬁcally, classic endocrine manifestations are rarely seen in
SLCTs of retiform type or those with heterologous elements (Chen
et al., 2014). Instead, these tumors are highly variable in their propor-
tions of Sertoli cells, Leydig cells, and/or ﬁbroblastic cells, and patients
most often present with abdominal pain or distention (Chen et al.,
2014). Pure Sertoli cell tumors are usually estrogenic and on occasion
secrete renin resulting in hypertension and hypokalemia. In contrast,
pure Leydig cell tumors are androgen secreting, though reports of
these are rare (Oliva et al., 2005). Approximately 20% of Sertoli–Leydig
cell tumors contain heterologous elements such as gastrointestinal
epithelium, carcinoid, cartilage and skeletal muscle (Oliva et al., 2005).
Common Sertoli–Leydig cell tumor immunohistochemical ex-
pression includes negative staining for epithelial membrane antigen
and positive staining for inhibin and caltretinin (Weng et al., 2013).
Although rare, alpha-fetoprotein (AFP) has been reported in approxi-
mately 30 cases of SLCTs (Sekkate et al., 2013). AFP is a plasma protein
produced by the yolk sac and fetal hepatocytes during development.
It is closely coupled to cellular division and the degree of cell differ-
entiation (Sung et al., 2013). As such, elevated levels of serum AFP
are often associated with hepatocellular carcinoma, neuroblastoma,
endodermal sinus (yolk sac) tumors, and carcinomas involving
endodermally derived organs including the lung, esophagus, stomach
and pancreas (Sung et al., 2013). It has additionally been noted in
teratomas, though the association is likely due to a component of
endodermal sinus tumor present in the teratoma. Likewise, it has
been associated with Wilms' tumor, which is also notable for the
presence of hepatoid cells (Young and Scully, 1985).The differential diagnosis of Sertoli–Leydig cell tumors with
hepatoid components and alpha-fetoprotein expression includes granu-
losa cell tumors, female adnexal tumor of probable wolfﬁan origin
(FATWO), endometrioid carcinoma, hepatoid carcinoma of the ovary,
serous carcinoma, and endodermal sinus tumor [Table 1]. Improper di-
agnosis due to the homogeneity of these tumors has led to the utiliza-
tion of immunohistochemical stains to distinguish tumors with similar
cell types (Weng et al., 2013). SLCTs can sometimes be differentiated
from granulosa cell tumors through the absence of Call-Exner bodies
on microscopic analysis. In addition, granulosa cell tumors often do
not present with heterologous elements (Sekkate et al., 2013). FATWOs
can be distinguished from SLCTs by the absence of heterologous ele-
ments and endocrine disturbance in addition to the microscopic pres-
ence of a mixture of closely packed tubules and sieve-like growth of
various sized cysts with diffuse spindle or polygonal cells (Chen et al.,
2014). Endometrioid tumors have immunohistochemical staining posi-
tive for EMA and CK7 while their neoplastic glands are negative for in-
hibin and caltretinin (Chen et al., 2014), which is in contrast to SLCTs.
Hepatoid carcinoma of the ovary (HCO) can similarly present as a
large pelvicmass with elevated serumAFP and hepatoid cells; however,
on microscopic evaluation, HCO forms a characteristically solid sheet of
uniform cells with abundant eosinophilic cytoplasm, distinct borders,
and centrally located nuclei with prominent nucleoli (Sung et al.,
2013). SLCT differs from serous carcinoma in that no serous tumors
have been found positive for AFP production, as in this case. AFP produc-
ing endodermal sinus tumors (EST) present similarly as pelvicmasses in
young women. They display elevated serum AFP levels and contain
hepatoid cells, however, ESTs display characteristic papillary cells
termed Schiller–Duval bodies, which were absent in this specimen
(Young and Scully, 1985).
The heterogeneous nature of SLCTs makes determining prognostic
outcomes difﬁcult. However, histological assessment deﬁning the de-
gree of differentiation is informative. Metastatic disease is rare in well-
differentiated subtypes of SLCTs as compared to the intermediate and
poorly differentiated subtypes (Young and Scully, 1985). The presence
of heterologous elements and retiform pattern is more common with
intermediate and poorly differentiated subtypes, conferring an addi-
tionally poor prognosis. Tumor stage based on extraovarian spread
and rupture or spillage of the tumor presents a greater risk of metasta-
sis, in addition to larger tumor size. Corresponding to the degree of dif-
ferentiation, prognosis correlates most meaningfully with tumor stage
at time of presentation (Chen et al., 2014; Young and Scully, 1985).
Table 1
Differential diagnosis of Sertoli–Leydig cell tumor with heterologous elements and positive alpha fetoprotein staining including various tumor distinguishing characteristics (AMH: Anti
Mullerian hormone, AFP: Alpha Fetoprotein, CEA: carcinoembryonic antigen, HPL: human placental lactogen, WT-1: Wilms' tumor 1, EMA: epithelial membrane antigen, PLAP: placental
alkaline phosphatase).
Sertoli–Leydig cell
tumor (SLCT)
Granulosa cell tumors Female adnexal tumor
of probable wolfﬁan
origin (FATWO)
Endometrioid
carcinoma
Hepatoid carcinoma of
the ovary (HCC)
Endodermal sinus
tumor (EST)
Serous carcinoma
Age 2–75 years
Avg 25
15+ years
Avg 53
Recur 20 years later
18–81 years
Avg 50
26–87 years
Avg 51
42–78 years
Avg 62
Young
Avg 17
45–57 years
(low-grade)
55–65 years
(high-grade)
Tumor
characteristics
Unilateral
Solid/cystic
Avg 16 cm
Unilateral
Solid/cystic
Avg 10 cm
Unilateral
Solid/cystic
1–20 cm
Bilateral
(25–40%)
Solid/cystic
Avg 11 cm
Solid (+/− cystic,
hemorrhagic,
necrotic), large
Solid/cystic
Fleshy
Necrotic
Avg 15 cm
Bilateral
Solid
Tumor markers Testosterone Inhibin A&B
Estradiol
AMH
None CA-125 AFP
CA-125
AFP
Alpha-1-antitrypsin
CA-125
Tumor type Sex-cord stromal
tumor
Sex-cord stromal tumor Wolfﬁan–Mesonephric
origin
Epithelial Epithelial vs yolk sac Germ cell neoplasia Epithelial
Heterologous
elements
Gastrointestinal
Liver
Skeletal muscle
cartilage
Hepatoid
No No No Hepatoid Hepatoid
Gastrointestinal
No
Microscopic
characteristics
Sertoli, leydig and
ﬁbroblastic cells.
Retiform pattern
with elongated,
irregularly shaped
tubules and cysts
containing papillae
Various cell patterns
including
macrofollicular,
trabecular, solid and
insular. Steroid-type
cells, Call-Exner bodies,
areas with interstitial
hemorrhage
Mixture of closely
packed tubules and
sieve-like growth of
various sized cysts
with diffuse spindle or
polygonal cells
Non-cystic,
villoglandular
pattern,
glandular
conﬂuence of
stromal
disappearance
Solid sheet of uniform
cells with abundant
eosinophilic
cytoplasm, distinct
borders, and centrally
located nuclei with
prominent nucleoli
Various patterns
including reticular
or microcystic,
polyvesicular.
Presence of
Schiller–Duval and
hyaline bodies
Extensive papillae
with psammona
bodies, glandular
complexity,
variable ﬁbrous
stroma or stromal
invasion
Immunostaining Testosterone
Estradiol
Cytokeratin
AFP (hepatoid)
CD99
Alpha-inhibin
Cytokeratin
AMH
Progesterone
receptor
Androgen receptor
Vimentin
Alpha-inhibin
Vimentin
Calretinin
CD99
Smooth muscle actin
Desmoplakin
CD10
CAM5.2
Vimentin
Variable EMA
Caltretinin
Inhibin
Keratin
CEA
HPL
EMA
CK7
Inhibin
Caltretinin
Focal AFP
Polyclonal CEA
Cytokeratin
Keratin
AFP (yolk sac,
hepatic or intestinal
epi in teratomas)
CD10
p53
WT1
CA-125
Mesothelin
CK5/6
D2-40
Negative stains EMA
PLAP
CEA
CA19-9
CA125
S100
EMA Mucin
B72.3
CEA
S100
Alpha-inhibin
AFP
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risk of recurrence for SLCTs, speciﬁcally those with hepatoid differenti-
ation and heterologous elements is approximately 40 to 50% in pub-
lished case reports. As such, the presence of noted poor prognostic
indicators inﬂuences the use of adjuvant chemotherapy.
Management for SLCTs can include fertility-sparing surgery for stage
IA/IC patients who desire future childbearing. Otherwise, complete sur-
gical staging combined with adjuvant chemotherapy is standard treat-
ment. Combination chemotherapy regimens for SLCTs have been
generalized from recommendations for other sex cord-stromal tumors
(SCSTs), most often adult granulosa cell tumors. However, the optimal
treatment algorithm is unknown given the rarity of SCSTs and has
evolved from vincristine, doxorubicin and cyclophosphamide (VAC) to
bleomycin, etoposide and cisplatin (BEP) (Brown et al., 2005). Though
the platinum-based chemotherapy is widely used for sex cord-stromal
tumors given the overall response rate, the side effect proﬁle for
bleomycin limits its utility and the relapse rate can also exceed 40 to
50% (Chen et al., 2014). As such, a study by Brown et al. in 2005 sug-
gested an alternative regimen utilizing taxanes with or without a plati-
num agent, for the treatment of SCSTs. The study showed sensitivity of
SCSTs, speciﬁcally granulosa cell tumors, to taxane chemotherapy withsimilarly efﬁcacy to BEP and the potential for a more durable response
with less toxicity (Brown et al., 2005).
Our patient was treated with carboplatin and paclitaxel given con-
cerns about pulmonary toxicity and because the patient's personal obli-
gations precluded inpatient hospitalization for treatment. At this point,
she has remained without evidence of disease recurrence. Thorough
evaluation of her histopathology was crucial given the uncommon
nature of disease, and underscores the need for accurate diagnosis of
rare tumors as the appropriate adjuvant treatment in these cases,
which is ultimately tied to patient outcome; may vary.References
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